BIND Therapeutics To Present At BioCentury’s Annual Newsmakers In The Biotech Industry Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that Andrew Hirsch, BIND’s president and chief executive officer, will present at BioCentury’s 22nd Annual Newsmakers in the Biotech Industry Conference on Thursday, September 10 at 2:00 p.m. ET at the Millennium Broadway Hotel in New York City.

Help employers find you! Check out all the jobs and post your resume.